Shelter Pharma Secures Repeat International Purchase Orders Worth USD 84,450 from Taha Drugs & Chemicals

Shelter Pharma Limited has secured repeat international purchase orders worth USD 84,450 from existing overseas customer Taha Drugs & Chemicals Co. Ltd, the company disclosed on 5th May, 2026, pursuant to Regulation 30 read with Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company stated that these repeat orders reflect continued trust and satisfaction of the customer in its products and services, and signify strengthening business relations in the international market.

Order Details

The purchase orders cover two nutraceutical products to be supplied to the international entity. The following table summarises the key details of the orders as disclosed in the regulatory filing:

Parameter:	Details
Customer Name:	Taha Drugs & Chemicals Co. Ltd.
Entity Type:	International Entity
Total Order Value:	USD 84,450
Order Date:	5th May, 2026
Payment Terms:	50% advance at the time of order; balance 50% against shipping bill
Execution Timeline:	Within mutually agreed timelines as per purchase order and shipment schedule
Related Party Transaction:	No — conducted at arm's length basis
Promoter/Group Interest:	No interest in the ordering entity

Product-Wise Breakdown

The orders comprise two distinct nutraceutical product lines, as detailed below:

Product:	Quantity	Order Value
D3 Cure Capsules 3x10:	71,250 boxes	USD 48,450
Joemega Capsules 3x10:	45,000 boxes	USD 36,000
Total:		USD 84,450

About Shelter Pharma Limited

Shelter Pharma Limited is a pharmaceutical and nutraceutical company focused on research, innovation, and quality. The company operates state-of-the-art manufacturing facilities and is engaged in the development and supply of nutraceutical products aimed at promoting health and well-being. The company's Managing Director, Mustaqim Nisarahmed Sabugar (DIN: 01456841), signed the regulatory disclosure from Ahmedabad on 5th May, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.20%	+5.26%	+5.62%	-25.30%	-19.48%	-26.12%

Shelter Pharma Limited has successfully converted warrants into equity shares, marking a significant milestone in its capital structure enhancement. The pharmaceutical company's board of directors approved the conversion of 2,79,000 warrants into 1,14,000 equity shares during their meeting held on May 01, 2026.

Warrant Conversion Details

The conversion process involved three non-promoter investors who exercised their option to convert warrants into equity shares. The board approved the allotment of 1,14,000 equity shares of face value Rs. 10 each, fully paid, upon receipt of the remaining exercise price.

Parameter	Details
Warrants Converted	2,79,000
Equity Shares Allotted	1,14,000
Face Value per Share	Rs. 10
Exercise Price per Warrant	Rs. 31.6875
Total Amount Raised	Rs. 36,12,375

Investor Participation

Three non-promoter investors participated in the warrant conversion process, with varying levels of conversion from their allocated warrants.

Investor Name	Warrants Allotted	Warrants Already Converted	Shares Converted	Amount Paid (Rs.)	Outstanding Warrants
Dipika Pankajbhai Patel	99,000	78,000	21,000	665,437.50	0
Rucha Kamleshbhai Trivedi	102,000	0	51,000	1,616,062.50	51,000
Sahil Tanojkumar Shah	51,000	0	42,000	1,330,875.00	9,000
Total	252,000	78,000	114,000	36,12,375.00	60,000

Capital Structure Impact

The warrant conversion has resulted in an expansion of the company's equity base. The paid-up equity share capital increased from Rs. 166117920 consisting of 16611792 equity shares to Rs. 167257920 consisting of 16725792 equity shares, all with face value of Rs. 10 each.

The newly allotted equity shares rank pari-passu with existing equity shares of the company in all respects. The allotment was made for cash upon receipt of the remaining exercise price of Rs. 31.6875 per warrant, representing 75% of the original warrant issue price of Rs. 42.25 per warrant.

Background and Regulatory Compliance

The warrant conversion follows the company's earlier disclosure dated August 06, 2025, regarding the allotment of 88,08,000 convertible equity warrants. The original warrant allotment was approved by shareholders at the Extra Ordinary General Meeting held on July 23, 2025, and received in-principle approval from BSE Limited through their letter dated July 22, 2025.

The warrants were issued at Rs. 42.25 each, including a premium of Rs. 32.25 per warrant, with initial subscription money collected at 25% of the issue price. The company will apply for listing and trading approval from the stock exchange for the newly issued equity shares in due course.

Meeting Details

The board meeting commenced at 12:00 P.M. and concluded at 12:15 P.M. on May 01, 2026. The decision was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.